Is HPS2-THRIVE the death knell for niacin?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Lipid Metabolism

Background:

• Niacin (nicotinic acid) is a lipid-modifying therapy proven to reduce cardiovascular events.
• It impacts atherosclerotic disease progression as monotherapy and in combination with other lipid-lowering drugs.
• Recent large trials showed no incremental benefit of niacin when added to statin therapy in patients with well-controlled atherogenic lipoproteins.

Observation:

• This study investigates the applicability of niacin trial results (AIM-HIGH, HPS2-THRIVE) from stable ischemic heart disease populations to patients post-acute coronary syndrome or myocardial infarction.
• It also examines whether patients with very low baseline high-density lipoprotein cholesterol (<30 mg/dL) face a particularly high risk of subsequent cardiac events.

Findings:

• The efficacy and safety of niacin in acute coronary syndromes remain uncertain.
• The specific risk associated with very low HDL cholesterol levels (<30 mg/dL) and potential benefits of niacin in this subgroup warrant further research.

Implications:

• Clinical decisions regarding niacin use in post-ACS/MI patients or those with extremely low HDL cholesterol should be made cautiously.
• Further research is needed to clarify niacin's role in specific high-risk cardiovascular patient populations.
• Understanding the interplay between niacin, statins, and HDL cholesterol in diverse patient groups is crucial for optimizing cardiovascular event prevention.